Abstract:Background: Tuberculosis is a serious life-threatening disease among the top global health challenges and rapid and effective diagnostic biomarkers are vital for early diagnosis especially given the increasing prevalence of multidrug resistance. Methods: Two human whole blood microarray datasets, GSE42826 and GSE42830 were retrieved from publicly available gene expression omnibus (GEO) database. Deregulated genes (DEGs) were identified using GEO2R online tool and Gene Ontology (GO), protein-protein interaction (PPI) network analysis was performed using Metascape and STRING databases. Significant genes (n = 8) were identified using T-test/ANOVA and Molecular Complex Detection (MCODE) score ≥10, which was validated in GSE34608 dataset. The diagnostic potential of three biomarkers was assessed using Area Under Curve (AUC) of Receiver Operating Characteristic (ROC) plot. The transcriptional levels of these genes were also examined in a separate dataset GSE31348, to monitor the patterns of variation during tuberculosis treatment. Results: A total of 62 common DEGs (57 upregulated, 7 downregulated genes) were identified in two discovery datasets. GO functions and pathway enrichment analysis shed light on the functional roles of these DEGs in immune response and type-II interferon signaling. The genes in Module-1 (n = 18) were linked to innate immune response, interferon-gamma signaling. The common genes (n = 8) were validated in GSE34608 dataset, that corroborates the results obtained from discovery sets. The gene expression levels demonstrated responsiveness to Mtb infection during anti-TB therapy in GSE31348 dataset. In GSE34608 dataset, the expression levels of three specific genes, GBP5, IFITM3, and EPSTI1, emerged as potential diagnostic makers. In combination, these genes scored remarkable diagnostic performance with 100% sensitivity and 89% specificity, resulting in an impressive Area Under Curve (AUC) of 0.958. However, GBP5 alone showed the highest AUC of 0.986 with 100% sensitivity and 89% specificity. Conclusions: The study presents valuable insights into the critical gene network perturbed during tuberculosis. These genes are determinants for assessing the effectiveness of an anti-TB response and distinguishing between active TB and healthy individuals. GBP5, IFITM3 and EPSTI1 emerged as candidate core genes in TB and holds potential as novel molecular targets for the development of interventions in the treatment of TB.

Identification of New Antibacterial Targets in RNA Polymerase of Mycobacterium Tuberculosis by Detecting Positive Selection Sites

Structural Basis of Mycobacterium Tuberculosis Transcription and Transcription Inhibition

Identification of gene targets that potentiate the action of rifampicin on Mycobacterium bovis BCG

Biochemical characterization of Mycobacterial RNA polymerases

[New Inhibitors Targeting Bacterial RNA Polymerase].

Transcriptome analysis and molecular characterization of novel small RNAs in Mycobacterium tuberculosis Lineage 1

Genes under positive selection in Mycobacterium tuberculosis

Identification of echinoderm metabolites as potential inhibitors targeting wild-type and mutant forms of Escherichia coli RNA polymerase (RpoB) for tuberculosis treatment

Computational analysis of RNA methyltransferase Rv3366 as a potential drug target for combating drug-resistant Mycobacterium tuberculosis

Gene expression profile analysis and target gene discovery of Mycobacterium tuberculosis biofilm

Discovery of Inhibitors Targeting Protein-Protein Interaction between Bacterial RNA Polymerase and NusG as Novel Antimicrobials

Detection of Rifampicin-Resistance Mutations in Mycobacterium Tuberculosis

Identification of antituberculosis agents that target ribosomal protein interactions using a yeast two-hybrid system

In Silico Identification of Potential Inhibitors of Mycobacterium tuberculosis DNA Gyrase from Phytoconstituents of Indian Medicinal Plants

Characterization of rpoB mutations associated with rifampin resistance in Mycobacterium tuberculosis from eastern China.

Screening of drug targets for tuberculosis on the basis of transcription factor regulatory network and mRNA sequencing technology

An Automated Approach for Global Identification of Srna-Encoding Regions in RNA-Seq Data from Mycobacterium Tuberculosis.

Structure-guided identification and characterization of potent inhibitors targeting PhoP and MtrA to combat mycobacteria

Computational reassessment of RNA-seq data reveals key genes in active tuberculosis

Rv2746c and Rv2881c, a potential drug target of Mycobacterium tuberculosis revealed by insilico investigation of proteins involved in lipid biosynthesis

Study on Rpob Gene Mutations in Mycobacterium Tuberculosis